全文获取类型
收费全文 | 1677篇 |
免费 | 151篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 39篇 |
妇产科学 | 40篇 |
基础医学 | 181篇 |
口腔科学 | 41篇 |
临床医学 | 151篇 |
内科学 | 390篇 |
皮肤病学 | 18篇 |
神经病学 | 70篇 |
特种医学 | 248篇 |
外科学 | 215篇 |
综合类 | 76篇 |
预防医学 | 187篇 |
眼科学 | 34篇 |
药学 | 87篇 |
1篇 | |
肿瘤学 | 60篇 |
出版年
2021年 | 13篇 |
2019年 | 9篇 |
2018年 | 15篇 |
2016年 | 9篇 |
2015年 | 17篇 |
2014年 | 20篇 |
2013年 | 33篇 |
2012年 | 61篇 |
2011年 | 54篇 |
2010年 | 38篇 |
2009年 | 39篇 |
2008年 | 53篇 |
2007年 | 68篇 |
2006年 | 55篇 |
2005年 | 52篇 |
2004年 | 69篇 |
2003年 | 57篇 |
2002年 | 52篇 |
2001年 | 76篇 |
2000年 | 39篇 |
1999年 | 41篇 |
1998年 | 47篇 |
1997年 | 42篇 |
1996年 | 26篇 |
1995年 | 34篇 |
1994年 | 35篇 |
1993年 | 50篇 |
1992年 | 47篇 |
1991年 | 28篇 |
1990年 | 40篇 |
1989年 | 41篇 |
1988年 | 66篇 |
1987年 | 65篇 |
1986年 | 53篇 |
1985年 | 41篇 |
1984年 | 26篇 |
1983年 | 29篇 |
1982年 | 22篇 |
1981年 | 16篇 |
1980年 | 22篇 |
1979年 | 11篇 |
1978年 | 22篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 14篇 |
1974年 | 14篇 |
1971年 | 13篇 |
1970年 | 8篇 |
1969年 | 11篇 |
1967年 | 8篇 |
排序方式: 共有1842条查询结果,搜索用时 31 毫秒
1.
2.
M J Buxton 《Health services management research》1988,1(1):43-50
Rapidly advancing health technology poses problems for managers. Although clear conceptual frameworks exist for economic evaluation, in practice severe problems remain in carrying out timely research that is locally appropriate to the needs of managers. This paper explores some of these problems in the context of the policy analysis interface between economic research and the management of technology. In the light of experience gained from recent evaluation research it indicates how researchers and managers can each contribute to the provision of a stronger empirical basis for policy making and policy management. An earlier version of this paper was presented at the joint meeting of the Health Economists Study Group and Institute of Health Service Management, University of York, 6-8 July 1987. The author would like to thank Christopher Spry and Mike Drummond for helpful comments. 相似文献
3.
4.
D R Sandeman A P Sandeman P Buxton H H Hughes D W Chadwick I R Williams R D Baker P M Foy D M Shaw 《British journal of neurosurgery》1990,4(4):299-312
The management of patients presenting with supratentorial glioma between 1978 and 1986 is reviewed. Complete follow-up in 517 cases was obtained. One hundred and fifty eight patients were not submitted to any form of surgery, 299 patients were biopsied and 60 patients underwent craniotomy and internal decompression. The no surgery group contained a higher proportion of patients with poor prognostic indicators than either the biopsy or craniotomy groups. The craniotomy group consisted of patients with better prognostic indicators than the biopsy group, in particular, younger age and more favourable site, type and grade of tumour. This was reflected in the difference in outcome between the groups. Median survival was 14 months in the craniotomy group, four months in the biopsy group and 2.2 months in the no surgery group. The outcome in patients with histologically proven malignant gliomas was best in those patients who received radiotherapy. The craniotomy group had a median survival of 18.5 months, a two year survival of 48% and a five year survival of 9%. The median survival following radiotherapy of those patients with proven malignant gliomas who had a biopsy was 9.5 months with a two year survival of 16% and a five year survival of 2%. These results compare favourably with studies which have adopted a more aggressive approach, suggesting that outcome is determined as much by patient selection using favourable prognostic indicators as by the treatment itself. The need for prospective trials of the management of unselected consecutive glioma patients randomizing them to conservative and radical treatment groups in order to define the role of both conventional therapy and radical therapy is discussed. 相似文献
5.
M J Buxton S D Sullivan L F Andersson C J Lamm B Liljas W W Busse S Pedersen K B Weiss 《The European respiratory journal》2004,24(4):568-574
Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention. 相似文献
6.
7.
Pseudomonas corneal abscess can result in a rapid downhill clinical course despite institution of appropriate medical measures. In this situation the clinician is faced with surgical intervention. A series of patients treated and stabilized through conjunctival flap therapy are presented. The role of conjunctival flap therapy in halting the progression of this entity is described. 相似文献
8.
9.
Alfred E Buxton Hugh Calkins David J Callans John P DiMarco John D Fisher H Leon Greene David E Haines David L Hayes Paul A Heidenreich John M Miller Athena Poppas Eric N Prystowsky Mark H Schoenfeld Peter J Zimetbaum Paul A Heidenreich David C Goff Frederick L Grover David J Malenka Eric D Peterson Martha J Radford Rita F Redberg 《Journal of the American College of Cardiology》2006,48(11):2360-2396
10.
Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献